Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same author

Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study.

NPJ precision oncology·2026
Same author

Engineering the Future of ADCs in Non-Small Cell Lung Cancer.

Oncology research·2026
Same author

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026
Same author

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Prostate cancer and prostatic diseases·2026
Same author

Prognostic Role of Serum Neuron-Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

The Prostate·2026

Related Experiment Video

Updated: Jun 26, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.9K

Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas.

Nancy Alnassar1, Jonathan M J Derry2, Giuseppe Luigi Banna1,3

  • 1Molecular Medicine Group, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.

Translational Lung Cancer Research
|May 13, 2024
PubMed
Summary
This summary is machine-generated.

High expression of the Duchenne muscular dystrophy (DMD) gene and its Dp71 transcript correlates with shorter survival in mesothelioma patients. The Dp71 transcript shows potential as a prognostic biomarker for mesothelioma.

Keywords:
BiomarkerDuchenne muscular dystrophy gene (DMD gene)mesotheliomasurvival

More Related Videos

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells
11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

8.0K
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

569

Related Experiment Videos

Last Updated: Jun 26, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.9K
Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells
11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

8.0K
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

569

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Prognostic biomarkers are essential for tailoring mesothelioma treatment strategies.
  • The Duchenne muscular dystrophy (DMD) gene and its transcripts have been linked to survival in various cancers.
  • Investigating DMD's prognostic role in mesothelioma is crucial.

Purpose of the Study:

  • To assess the prognostic value of DMD gene expression and its transcripts in mesothelioma.
  • To evaluate the Dp71 transcript as a specific prognostic biomarker across mesothelioma subtypes.
  • To identify associations between DMD expression and patient survival.

Main Methods:

  • Analysis of The Cancer Genome Atlas (TCGA) mesothelioma RNAseq, mutation, and clinical data.
  • Assessment of DMD gene and transcript (Dp427, Dp71) expression in relation to survival.
  • Differential gene expression analysis and pathway enrichment analysis.

Main Results:

  • High DMD gene and Dp71 transcript expression significantly correlated with shorter mesothelioma patient survival (P=0.003 and P<0.001).
  • Dp71 expression remained a significant independent prognostic factor in multivariate analysis (HR 2.29, P=0.008).
  • Pathway analysis revealed enrichment of cell cycle and homologous recombination pathways; Dp71 expression correlated with tumor microenvironment cells, including M2 macrophages.

Conclusions:

  • Differential expression of DMD transcripts, particularly Dp71, is linked to poor survival in mesothelioma.
  • The Dp71 transcript shows promise as a biomarker for predicting mesothelioma patient survival across subtypes.
  • Further research is needed to elucidate the role of DMD transcripts in mesothelioma pathogenesis and inform treatment strategies.